BioSpace News Archive

Mr. Irving has overseen business strategy, R&D planning, product commercialization and business development for companies of all sizes for over 35 years, with an interest in neuroscience.

Clinics adopt state-of-the art vaccine management platform to protect viability of vaccines, improve office workflow

New Rare Conditions Care Value Program expands support services to facilitate second opinion that can improve health outcomes, reduce wasteful spending

Luster Premium White® is getting a dazzling new look for 2018.

Bridget and Maryann contribute veteran expertise and strategic perspective as we help biopharmaceutical companies and investors make more efficient use of capital and accelerate product development.

Kalorama Information said the market for electronic medical records was $29.7 billion in 2017, and it is expected to rise to $39.7 billion by 2022.

Axxess has been recognized again as one of Modern Healthcare’s 2018 “Best Places to Work in Healthcare.”

The first analgesic opioid molecule to exhibit a reduced incidence of specific CNS-mediated side effects, such as euphoria, through the targeted alteration of brain-entry kinetics.

In the news release, Curis Announces FDA Fast Track Designation for Fimepinostat (CUDC-907) Development in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma, issued 31-May-2018 by Curis, Inc. over PR Newswire, we are advised by the company that some information that is imperative for the investor community was not included in the original release.

Fact is, home health providers are under increasing pressure from healthcare systems and payors to reduce unplanned hospital readmissions.